Carcinoma, Large Cell: Clinical Trials

5 trials for Carcinoma, Large Cell, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 2 terminated, 1 recruiting. 5 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 35Completed 2, Terminated 2, Recruiting 1

Follow Carcinoma, Large Cell: new trials by email Literature Review of Carcinoma, Large Cell trials Research Report on Carcinoma, Large Cell

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
6-Thio-2'-Deoxyguanosine, Cemiplimab, Docetaxel - Carcinoma, Non-Small -Cell Lung
Phase 3RecruitingMaia Biotechnology3002025-12-082026-01-12
ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants
Brigatinib, Crizotinib - Non-small Cell Lung Cancer, Lung Cancer
Phase 3CompletedAriad Pharmaceuticals2752016-05-262021-08-20
Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer
CP 751,871 (Figitumumab), Erlotinib - Carcinoma, Large Cell, Carcinoma, Non-Small-Cell Lung
Phase 3TerminatedPfizer5832008-05-012013-07-24
Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology
CP-751,871 (Figitumumab), Carboplatin, Paclitaxel - Carcinoma, Squamous Cell, Carcinoma, Adenosquamous
Phase 3TerminatedPfizer6812008-04-012014-01-13
ZD6474 (ZACTIMAâ„¢) Phase III Study in EGFR Failures
ZD6474 (vandetanib), Best Supportive Care - Non-Small-Cell Lung Carcinoma
Phase 3CompletedGenzyme, a Sanofi Company11402006-11-012016-09-30

Narrower conditions

Carcinoma, Non-Small-Cell Lung (5)  ·  Carcinoma, Squamous Cell (5)  ·  Adenocarcinoma (3)  ·  Carcinoma (2)  ·  Carcinoma, Adenosquamous (1)  ·  Lung Neoplasms (1)

Broader conditions

Bronchial Neoplasms (5)  ·  Carcinoma, Bronchogenic (5)  ·  Lung Diseases (5)  ·  Neoplasms (5)  ·  Neoplasms by Histologic Type (5)  ·  Neoplasms by Site (5)  ·  Neoplasms, Glandular and Epithelial (5)  ·  Neoplasms, Squamous Cell (5)  ·  Respiratory Tract Diseases (5)  ·  Respiratory Tract Neoplasms (5)  ·  Thoracic Neoplasms (5)  ·  Lung Neoplasms (4)  ·  Carcinoma (3)  ·  Neoplasms, Complex and Mixed (1)

Interventions

figitumumab (2)  ·  Carboplatin (1)  ·  Crizotinib (1)  ·  Docetaxel (1)  ·  Erlotinib Hydrochloride (1)  ·  Gemcitabine (1)  ·  Paclitaxel (1)  ·  Vinorelbine (1)  ·  alpha-2'-deoxythioguanosine (1)  ·  brigatinib (1)  ·  cemiplimab (1)  ·  vandetanib (1)

Sponsors

Pfizer (2)  ·  Ariad Pharmaceuticals (1)  ·  Genzyme, a Sanofi Company (1)  ·  Maia Biotechnology (1)

Countries

Taiwan (5)  ·  Canada (4)  ·  France (4)  ·  Italy (4)  ·  South Korea (4)  ·  Spain (4)  ·  United States (4)  ·  Australia (3)  ·  Austria (3)  ·  Germany (3)  ·  Hong Kong (3)  ·  Poland (3)  ·  Switzerland (3)  ·  United Kingdom (3)  ·  Belgium (2)

Top investigators

Victor Zaporojan, Medical Doctor (1)

Results publications

PMID 24888810, PMID 25395283, PMID 25881079, PMID 28501139, PMID 30280657, PMID 32780660, PMID 38468440, PMID 39707229, PMID 41332393, PMID 41410381, PMID 41740899

NIH funding

2015 (1)